Inhibikase Therapeutics (IKT) Revenue (2020 - 2023)
Inhibikase Therapeutics (IKT) recorded Revenue of $1.00 in Q4 2023, down 100.0% from $63,566 a year earlier and down 100.0% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Revenue (2020 - 2023) Analysis & Trends
For FY2023, Inhibikase Therapeutics reported Revenue of $260,501, up 111.0% from FY2022.
- Annual Revenue has a three-year compound annual growth rate of -28.0% (FY2020 to FY2023).
- Across earlier years, Revenue came in at $123,440 in FY2022 (-96.0%), $3.1 million in FY2021 (+343.9%) and $698,468 in FY2020.
- The Q4 2023 figure is the lowest quarterly Revenue in data going back to Q1 2020.
- On a year-over-year basis, Revenue rose in two of the last six quarters, with growth averaging 106.2%.
- Peak year-over-year performance for Revenue in the last five years was growth of 991.3% in Q3 2023, against a decline of 100.0% in Q4 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at $79,569 (Q3 2023), $116,410 (Q2 2023) and $64,521 (Q1 2023).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 25.31 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 16.99 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 16.61 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 14.41 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 15.38 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 10.05 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 7.80 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 15.03 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 3.33 Bn |
| 10 | Inhibikase Therapeutics | 359.62 Mn | -225.86 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 1.00 |
| Sep 30, 2023 | 79,569.00 |
| Jun 30, 2023 | 116,410.00 |
| Mar 31, 2023 | 64,521.00 |
| Dec 31, 2022 | 63,566.00 |
| Sep 30, 2022 | 7,291.00 |
| Jun 30, 2022 | 6,552.00 |
| Mar 31, 2022 | 46,031.00 |
| Dec 31, 2021 | 1,944.00 |
| Sep 30, 2021 | 328,459.00 |
| Jun 30, 2021 | 1.36 Mn |
| Mar 31, 2021 | 1.41 Mn |
| Dec 31, 2020 | 170,416.00 |
| Sep 30, 2020 | 37,680.00 |
| Jun 30, 2020 | 219,585.00 |
| Mar 31, 2020 | 270,787.00 |
API Access
Inhibikase Therapeutics Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=revenue&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "revenue", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=revenue&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();